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BACKGROUND: The diagnosis of systemic immuno-
globulin light-chain (AL) amyloidosis requires dem-
onstration of amyloid deposits in a tissue biopsy and
amyloidogenic monoclonal light chains. The opti-
mal strategy to identify the amyloidogenic clone has
not been established. We prospectively assessed the
diagnostic sensitivity of the serum free light chain
(FLC) / ratio, a commercial serum and urine aga-
rose gel electrophoresis immunofixation (IFE), and
the high-resolution agarose gel electrophoresis im-
munofixation (HR-IFE) developed at our referral
center in patients with AL amyloidosis, in whom the
amyloidogenic light chain was unequivocally identi-
fied in the amyloid deposits.
METHODS: The amyloidogenic light chain was identi-
fied in 121 consecutive patients with AL amyloidosis by
immunoelectronmicroscopy analysis of abdominal fat
aspirates and/or organ biopsies. We characterized the
monoclonal light chain by using IFE and HR-IFE in
serum and urine and the FLC / ratio in serum. We
then compared the diagnostic sensitivities of the 3
assays.
RESULTS: The HR-IFE of serum and urine identified
the amyloidogenic light chain in all 115 patients with
a monoclonal gammopathy. Six patients with a bi-
clonal gammopathy were omitted from the statisti-
cal analysis. The diagnostic sensitivity of commercial
serum and urine IFE was greater than that of the FLC
/ ratio (96% vs 76%). The combination of serum
IFE and the FLC assay detected the amyloidogenic
light chain in 96% of patients. The combination of
IFE of both serum and urine with the FLC / ratio
had a 100% sensitivity.
CONCLUSIONS: The identification of amyloidogenic
light chains cannot rely on a single test and requires the
combination of a commercially available FLC assay
with immunofixation of both serum and urine.
© 2008 American Association for Clinical Chemistry
Systemic immunoglobulin light-chain (AL) amyloid-
osis7 is a progressive disease caused by the deposition of
insoluble fibrils formed by the aggregation of circulat-
ing monoclonal light chains produced by a usually
small-sized bone-marrow plasma cell clone (1 ). This
process causes organ dysfunction and ultimately leads
to death.However, effective chemotherapy, which sup-
presses the production of the amyloidogenic light
chain before irreversible organ damage has occurred,
can significantly extend survival (2 ). Thus, early diag-
nosis is critical in the management of patients with AL
amyloidosis. The diagnosis relies on both the demon-
stration of amyloid deposits in tissues and on the iden-
tification of the plasma cell clone producing a light
chain, which should be proved amyloidogenic by direct
biochemical or immunohistochemical typing of the
amyloid deposits. The amyloidogenic clonal plasma
cell population can be detected either by bone marrow
analysis or by the identification of a monoclonal light
chain in the patient’s serum and/or urine (3 ). The
identification and quantification of the amyloidogenic
light chain is also necessary in the follow-up of patients
withAL amyloidosis to assess the hematologic response
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to therapy (3 ). We investigated the optimal strategy to
detect the amyloidogenic light chains, maximizing the
diagnostic sensitivity. We performed a prospective
study on 121 consecutive patients withAL amyloidosis,
in whom the amyloidogenic light chain was detected in
the amyloid deposits by use of immuno-electron mi-
croscopy (4 ) to assess the diagnostic sensitivity of the
quantitative assay of circulating free light chains (FLC),
of a commercial semiautomated agarose gel electro-
phoresis immunofixation (IFE) assay, and of the high-
resolution agarose gel electrophoresis immunofixation
(HR-IFE) technique developed at our referral center.
We also assessed the contribution of urine analysis to
the diagnosis.
Material andMethods
Study participants were 121 patients with biopsy-
proven systemicAL amyloidosis consecutively enrolled
between January 2004 and May 2005. None of the pa-
tients was previously treated. All the patients had been
referred to our institution because of suspected sys-
temic amyloidosis, and the diagnosis of AL amyloidosis
was confirmed at our center. In that same period of
time, a total of 179 such patients were referred to our
center and the diagnosis of AL amyloidosis was not
confirmed in 58 (32%) of them. All the patients gave
written informed consent, and the study was approved
by the review board of the Fondazione Istituto di Ricov-
ero e Cura a Carattere Scientifico Policlinico SanMatteo.
Mutations associated with hereditary amyloidoses
were excluded by DNA analysis. The amyloid deposits
were characterized in all patients by immunoelectron
microscopy analysis of abdominal fat aspirates and/or
organ biopsies (4 ). Six patients (5%) were excluded
from the calculation of the diagnostic sensitivity of the
tests becauseHR-IFE detected a biclonal gammopathy.
Serum and urine HR-IFE was performed with
anti-IgG, -IgA, -IgM, - and - antibodies (Dako) on gels
freshly prepared at our laboratory, following basically
the technique proposed by the Malmo¨ group (5 ).
Briefly, electrophoresis was performed in freshly pre-
pared 1-mm thick agarose (SeaKemME agarose, Cam-
brex Bio Science), 7.5 g/L in diethyl barbiturate buffer
(75 mmol/L, pH 8.6, with calcium lactate 2 mmol/L).
Custom dilution of the patient’s serum, and 100-fold
concentrated urine sample were placed in 5-mm–
width slits, and 20 V/cmwas applied until albumin had
migrated 6.5 cm. After electrophoresis, filter paper
strips soakedwith 50L of appropriate antiserumwere
applied to each lane and incubated in a moist chamber
for 1 h. The agarose plate was then washed 3 times with
saline and once with deionized water, then dried and
stained with Coomassie Blue R 250. With this method,
the detection limit of a monoclonal component is 50–
150mg/L in serum and 30–100mg/L in urine, depend-
ing on the intensity of the polyclonal background.
Semiautomated serum and urine IFE was performed
with a commercial Hydragel 2IF/BJ(HR) kit on a Hy-
drasys apparatus (Sebia). The detection limit reported
by the manufacturer varies from 120–250 mg/L, ac-
cording to the migration of the monoclonal compo-
nent and to the intensity of the polyclonal background.
Serum FLC concentration was measured by latex-
enhanced immunoassay (The Binding Site) on a Behr-
ing BN II (Dade Behring) nephelometer. The reference
intervals for  and  FLC are 3.3–19.4 mg/L and 5.7–
26.3 mg/L, respectively, and the / ratio diagnostic
range is 0.26–1.65 (6 ). A patient was classified as pro-
ducing monoclonal  or  light chains according to an
abnormal / ratio (6 ). Serum FLC immunoassays
have a limit of quantification of1 mg/L (6 ).
Differences in diagnostic sensitivity were tested for
statistical significance by Fisher exact test, andCIs were
determined by the exact binomial distribution.
To assess disease severity, the number and type of
organs affected by amyloidosis and the cardiac stage,
based on serum N-terminal pronatriuretic peptide
type B (NT-proBNP) and cardiac troponin I (cTnI),
were recorded in patients in whom the amyloidogenic
light chain was not identified by both serum IFE and
HR-IF, and in those in whom it was missed by assay of
the combination of FLC / ratio and serum IFE. Pa-
tients with both NT-proBNP 332 ng/L and cTnI
0.1 g/L were listed as cardiac stage I, those with
NT-proBNP 332 ng/L or cTnI 0.1 g/L were de-
fined as cardiac stage II, and patients with both NT-
proBNP332 ng/L and cTnI0.1 g/L were defined
as cardiac stage III (7 ).
Results
In 6 of the 121 patients with AL in whom the amyloi-
dogenic light chain was identified by immuno-electron
microscopy in the amyloid deposits, HR-IFE revealed a
biclonal gammopathy (Table 1). In 4 of these patients,
the FLC / ratio correctly identified the light chain
type constituting the amyloid deposits, whereas high-
resolution IFE did not identifymonoclonal light chains
in the urine of 2 patients (no. 117 and 118), and in 2
patients (no. 116 and 121) the opposite light chain was
identified. In all the remaining 115 patients, HR-IFE
detected the monoclonal amyloidogenic light chain in
serum and/or urine and, in all patients, the type of light
chain detected corresponded to that identified by
immuno-electron microscopy as forming the amyloid
fibrils. The amyloidogenic light-chain type was  in 30
patients (26%) and  in 85 patients (74%).
The diagnostic sensitivity of the tests is reported in
Table 2. In 6 patients (5%) the HR-IFE detected the
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amyloidogenic light chain only in urine, and in 6 cases
(5%) only in serum. Five of the 6 amyloidogenic light
chains detected only in urine were of the  type,
whereas 5 of the 6 light chains detected only in the
serum were . The diagnostic sensitivity of both im-
munofixation techniques was significantly lower for 
than for  light chains in serum (HR-IFE 83% vs 99%,
P 0.004; IFE 60%vs 87%,P 0.003). Conversely, the
FLC assay performed better with  than with  amyloi-
dogenic light chains (97%vs 69%,P 0.002). Notably,
5 patients with a FLC / ratio above the reference
limit and  Bence-Jones proteinuria did not show
monoclonal  light chains in serum with both im-
munofixation techniques (Table 3).
One patient with a serum IgAmonoclonal com-
ponent,  Bence-Jones protein, and amyloid deposits
typed as  had a / ratio of 1.72 ( FLC 146mg/L and
 FLC 85 mg/L) and was incorrectly classified has hav-
ing a  clone by the FLC assay. This patient had renal
failure (serum creatinine 221 mol/L) and polyclonal
hypergammaglobulinemia that could account for the
increase of both  and  FLC. In the overall population
the median serum creatinine concentration was 103
mol/L (range: 44–619 mol/L), and serum creati-
nine was within reference limits (males 115 mol/L,
females 97 mol/L) in 65 patients (56%). In our pa-
tient population, renal failure did not significantly in-
fluence the diagnostic sensitivity of the/ ratio, which
was 78% (95% CI, 67%–87%) in patients with normal
renal function and 73% (95% CI, 60%–84%) in pa-
tients with serum creatinine above the upper reference
limit (P 0.58). Serum creatininewas not significantly
higher in patients in whom the FLC / ratio failed to
identify the amyloidogenic light chain (median 100 vs
114 mol/L, P 0.2). Recently, a new reference inter-
val for the FLC / ratio (0.37–3.1) has been proposed
for patients with abnormal kidney function (8 ). The
diagnostic sensitivity of this reference interval in the
patients with serum creatinine above the upper refer-
ence limit was 71% (95% CI, 58%–83%), very similar
to that obtained with the commonly used reference
range. As expected, most of our patients had hypoga-
mmaglobulinemia, and only 14 (12%) were found to
have polyclonal hypergammaglobulinemia by serum
Table 1. Results in 6 patients with a biclonal gammopathy.
ID no. Serum HR-IFE Urine HR-IFE Serum IFE Urine IFE  FLC, mg/L  FLC, mg/L FLC / ratio IEH typing
116 IgG Free  IgG Not detected 79.4 27.2 2.92 () 
117 IgM/free  Not detected IgM/free  Not detected 8.84 117 0.07 () 
118 IgG/IgG Not detected IgG/IgG Not detected 114 28.1 4.06 () 
119 Free  Free /free  Not detected Free /free  14.8 22.1 0.67 (Normal) 
120 IgG/free  Free  Free  Free  14.9 41.6 0.36 (Normal) 
121 IgG/IgG Free  IgG Not detected 152 27 5.63 () 
Table 2. Diagnostic sensitivity of HR-IFE, IFE, and FLC / ratio in 115 patients with systemic AL amyloidosis.
Patients with  clones
(n  30)
Patients with  clones
(n  85)
Overall population
(N  115)
No.
positive % (95% CI)
No.
positive % (95% CI)
No.
positive % (95% CI)
Serum HR-IFE 25 83 (67–94) 84 99 (94–100) 109 95 (89–98)
Urine HR-IFE 29 97 (85–100) 80 94 (87–98) 109 95 (89–98)
Serum and urine HR-IFE 30 100 (90–100) 85 100 (96–100) 115 100 (97–100)
Semiautomated serum IFE 18 60 (42–76) 74 87 (79–93) 92 80 (72–87)
Semiautomated urine IFE 21 70 (52–84) 56 65 (55–75) 77 67 (58–75)
Semiautomated serum and urine IFE 27 90 (75–97) 83 98 (92–100) 110 96 (91–98)
FLC / ratio 29 97 (85–100) 59 69 (59–79) 88 76 (68–84)
Serum IFE  FLC / ratio 30 100 (90–100) 80 94 (87–98) 110 96 (91–98)
Urine IFE  FLC / ratio 29 97 (85–100) 77 91 (83–95) 106 92 (86–96)
Serum and urine IFE  FLC / ratio 30 100 (90–100) 85 100 (96–100) 115 100 (97–100)
Identification of Amyloidogenic Light Chains
Clinical Chemistry 55:3 (2009) 501
electrophoresis ( globulin concentrations of 18–24
g/L). The diagnostic sensitivity of the/ ratiowas 71%
(95% CI, 46%–90%) in patients with hypergamma-
globulinemia and 79% (95% CI, 70%–86%) in the
other patients (P 0.52).
The diagnostic sensitivity of commercial semiau-
tomated serum and urine IFE was significantly higher
than that of the serum FLC test (96% vs 76%, P 
0.001). The addition of serum IFE to the FLC / ratio
enabled correct identification of the amyloidogenic
light chain in all but 5 patients (4%), all of whom had a
 Bence-Jones protein detectable by urine IFE (Table
4). These 5 patients had symptomatic disease and were
in need of prompt treatment. However, the combina-
tion of serum and urine IFE and of the FLC / ratio
enabled correct identification of the amyloidogenic
light chain in all the patients.
Discussion
The high-resolution immunofixation of serum and
urine developed at our referral center enabled us to
identify all amyloidogenic light chains in the study
population. This result underlines the relevance of
state-of-the-art techniques in the investigation of com-
plex, rare diseases and the need for improving com-
mercial immunofixation assays. However, this tech-
nique is not widely available. In our series, the
diagnostic sensitivity of the FLC / ratio was 76%,
that of commercial IFE of both serum and urine was
96%, and their combination correctly identified the
amyloidogenic light chains in 100% of patients.
Previous studies on the diagnostic performance of
the FLC assay in AL amyloidosis have led to different
results. In the first 2 retrospective series by the United
Kingdom National Amyloidosis Centre (9 ) and by the
Mayo Clinic (10), the quantitative FLC assay showed a
greater diagnostic sensitivity than the association of se-
rum and urine immunofixation electrophoresis (98%
vs 79% and 91% vs 81%, respectively). These results
were not confirmed in a subsequent retrospective study
by the investigators of theBostonAmyloidProgram,who
reported a lower diagnostic sensitivity of the FLC assay
(75%) compared to immunofixation (96%) (11), or in a
subsequent study by the Mayo Clinic group (12), in
which the FLC assay and the combination of serum and
Table 3. Results in 5 patients in whom serum immunofixation failed to identify the amyloidogenic  light chain.
ID Sex
Serum
HR-IFE
Urine
HR-IFE Serum IFE Urine IFE
 FLC,
mg/L
 FLC,
mg/L
FLC /
ratio
IEH
typing
Creatinine,
mol/La Organs involved
Cardiac
stageb
8 F Not detected Free  Not detected Free  329.0 21.2 15.52 ()  94 Heart, liver II
18 M Not detected Free  Not detected Free  378.0 56.3 6.71 ()  347 Kidney, heart, liver II
22 M Not detected Free  Not detected Free  505.0 13.8 36.59 ()  138 Heart III
74 F Not detected Free  Not detected Not detected 395.0 27.8 14.21 ()  322 Kidney, heart II
108 F Not detected Free  Not detected Free  158.0 53.1 2.98 ()  394 Kidney, heart II
a Upper reference limit: males 115 mol/L, females 97 mol/L.
b Stages of cardiac involvement according to Dispenzieri et al. (7).
Table 4. Results in 5 patients in whom the combination of serum immunofixation and / ratio failed to
identify the amyloidogenic light chain.
ID Sex Serum IFE Urine IFE
 FLC,
mg/L
 FLC,
mg/L
FLC /
ratioa
IEH
typing
Creatinine,
mol/Lb Organs involved
Cardiac
stagec
2 F Not detected Free  29.0 60.3 0.48 (Normal)  71 Kidney I
5 M Not detected Free  11.2 11.7 0.96 (Normal)  156 Kidney I
39 F Not detected Free  22.3 37.8 0.59 (Normal)  97 Heart II
61 M Not detected Free  9.7 24.7 0.39 (Normal)  94 GId I
91 F Not detected Free  53.5 71.3 0.75 (Normal)  126 Kidney, heart, GI, PNS III
a Also applying the recently published (8) new reference range for FLC ratio (0.37–3.1) for patients with abnormal renal function, the results do not change.
b Upper reference limit: males 115 mol/L, females 97 mol/L.
c Stages of cardiac involvement according to Dispenzieri et al. (7).
d GI, gastrointestinal system; PNS, peripheral nervous system.
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urine immunofixation electrophoresis had a comparable
diagnostic performance (diagnostic sensitivity 91% vs
95%, respectively). More recently, in a study from the
Heidelberg group inwhich the studypopulation included
11%of patientswithmultiplemyeloma, the combination
of serum and urine immunofixation had a slightly higher
sensitivity than theFLC/ ratio (92%vs87%), and the2
tests proved complementary (13).
It is worth noting that none of the previous studies
was based on the unequivocal typing of the amyloido-
genic protein constituting the amyloid deposits (1, 3 ).
This result is achievable using various techniques,
including immuno-electron microscopy (4 ). In our
series of consecutive patients the characterization of
amyloidosis as AL type relied on immuno-electronmi-
croscopy results. Immuno-electron microscopy also
confirmed that the light chain identified in the patients’
serum and/or urine was actually amyloidogenic.
The observation of a higher diagnostic sensitivity
of the FLC assay for  than for  light chains and of a
lower resolution of serum immunofixation in patients
with light chains in our series is in agreementwith the
results reported by the Boston and the Heidelberg
groups (11, 13). This difference may be due to the for-
mation of aggregates of various size and electro-
phoretic mobility by  light chains, resulting in the
absence of a distinct electrophoretic band. This hy-
pothesis is being tested at our center.
The introduction of the FLC assay also triggered a
lively debate on the role of urine immunofixation in
the diagnosis of AL amyloidosis. This issue was ad-
dressed in the study by Katzmann et al. on 110 patients
with AL amyloidosis, in which the association of the
FLC assay and serum immunofixation electrophoresis
had a 99% diagnostic sensitivity and the addition of
urine immunofixation electrophoresis did not im-
prove this result (12). In a subsequent retrospective
study on 428 patients with plasma cell dyscrasia in
whom a monoclonal light chain was detected in the
urine by immunofixation, including 123 patients with
AL amyloidosis, Katzmann and coworkers observed
that the combination of the FLC assay and serum im-
munofixation identified a monoclonal light chain in
100% of the patients with amyloidosis (14). However,
this study included only patients with positive urine
immunofixation, thus increasing the likelihood of an
abnormal / ratio, because a high concentration of
FLC is required to produce overflow proteinuria (15).
Studies performed on general hospital populations in-
dicate that measurement of serum FLC may replace
urine analysis in the initial screening of monoclonal
gammopathies (16, 17). The reported results of these
studies showed that a false-positive / ratio was asso-
ciated with polyclonal increases in immunoglobulin
and with renal impairment. In our population, how-
ever, renal insufficiency and polyclonal hypergamma-
globulinemia did not affect the diagnostic sensitivity of
the / ratio. Also, the study by Bochtelr et al. (13),
performed in patients with AL amyloidosis, showed
that renal insufficiency did not affect the diagnostic
sensitivity of the FLC test. This discrepancy may be
attributable to characteristics of the different patient
populations. More recently, Dispenzieri et al. reported
an unsatisfactory correlation between changes in FLC
and urinemonoclonal protein inmultiplemyeloma after
chemotherapy, underlying the need for urine analysis in
the follow-up of myeloma patients (18). In the present
series, the combination of serum IFE with the FLC assay
detected the amyloid clone in 96% of the patients. Thus,
our results indicate that, in patients with AL amyloidosis,
urine immunofixation should also be performed to en-
sure optimal diagnostic sensitivity. Indeed, omitting
urine immunofixation would have led to us missing 6%
of patients with  amyloidogenic clones, an important
shortcoming given the severity of thedisease and theneed
for early diagnosis. Only the combination of immunofix-
ation electrophoresis of both serum and urine and the
FLC assaywas able to detect all the amyloidogenic clones.
Semiautomated serumandurine IFE and the FLC test are
widelyavailableandshouldbecombined for searching for
a monoclonal component in patients with suspected AL
amyloidosis.
Finally, it should be noted that in the present series
5% of the patients had a biclonal gammopathy and
were not included in the assessment of the diagnostic
sensitivity. In the 868 patients with AL amyloidosis
evaluated at our center between 1986 and 2007 we ob-
served a comparable proportion (6%) of cases with a
biclonal gammopathy detectable with serum and urine
HR-IFE. In the 6 patients with a biclonal gammopathy,
the / ratio identified the amyloidogenic light chain
in 4 cases (3  and 1 ), whereas immunofixation pro-
duced mixed results. However, in patients with a bi-
clonal gammopathy, although an altered FLC / ratio
may suggest which light chain is involved, only the di-
rect typing of the amyloid deposits allows the unequiv-
ocal identification of the amyloidogenic light chain,
which should be considered themarker of hematologic
response to therapy.
The availability of new reliable tools, such as the
FLC assay, has dramatically improved themanagement
of AL amyloidosis. Nevertheless, our findings under-
line the complexity of this disease, which still does not
allow reliance on only a few diagnostic tests.
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